TABLE 3.

In vitro activities of antifungal agents against selected melanized fungia

SpeciesActivityb
AmBItraVoriPosaIsavuRavuKetoTerb5-FCCaspMicaAnid
Alternaria spp.++++++++++
Aureobasidium pullulans +++++
Bipolaris spp.++++++++++++
Chaetomium spp.++++++++
Cladosporium spp.+++++++++
Cladophialophora bantiana +++++++++++++++
Curvularia spp.+++++++++++
Exophiala spp.+++++++++++++
Exophiala dermatitidis ++++++++++++++
Exserohilum spp.++++++++
Fonsecaea pedrosoi +++++++++++++++
Lasiodiplodia theobromae +
Madurella mycetomatis +++++++++
Ochroconis gallopava ++++
Phialemonium spp.+++
Phialophora spp.++++++++++
Rhinocladiella spp.+++++++
Rhinocladiella mackenziei ++++++
Scedosporium/Pseudallescheria spp.++++
Scedosporium prolificans
Scopulariopsis brumptii
Veronaea botryosa ++
Wallemia sebi ++++++
  • a Adapted from reference 625 with permission of Expert Reviews Ltd.

  • b Abbreviations: AmB, amphotericin B; 5-FC, flucytosine; Keto, ketoconazole; Itra, itraconazole; Vori, voriconazole; Posa, posaconazole; Ravu, ravuconazole; Casp, caspofungin; Mica, micafungin; Anid, anidulafungin; Terb, terbinafine; Isavu, isavuconazole. ++, good activity suggested based on consistently low MICs and testing against at least five isolates of a particular genus or species; +, potential/marginal activity suggested based on inconsistent MICs or very few isolates of a particular genus or species; −, no significant activity suggested based on consistently high MICs. The results do not represent formally defined CLSI breakpoints.